GigaGen to Present Poster at the 2021 American Association for Cancer Research (AACR) Virtual Annual Meeting

South San Francisco, Calif., March 23, 2021 (GLOBE NEWSWIRE) -- GigaGen, a biotechnology company advancing transformative antibody drugs for immune deficiency, infectious diseases, transplant rejection and checkpoint resistant cancers, and a subsidiary of Grifols, announced today that it will present an abstract in a poster session at the 2021 American Association for Cancer Research (AACR) Virtual Annual Meeting, which is being held on April 10-15 and May 17-21.

Details of the abstract and poster presentation are as follows:

Title: Single cell transcriptomics reveals the effect of PD-L1 and TGF-β blockade on the tumor microenvironment
Presenter: Erica Stone, Ph.D., vice president of Oncology
Session Category: Tumor Biology
Session Title: Chemokines in the Tumor Microenvironment
Poster Number: 2684
Presentation Type: E-poster
Date and Time: Links to the poster presentation will be available on the conference website beginning at 8:30 a.m. EDT on Saturday, April 10 and questions or meeting requests can be sent directly through that page. Posters will be available for viewing to meeting registrants until Monday, June 21.

A major goal in oncology is to find strategies, such as dual PD-L1/TGF- β blockade, that enhance T cell infiltration of tumors to improve anti-tumor activity and efficacy of anti-PD-1/PD-L1 therapy. The poster to be presented details transcriptomic effects of PD-L1 and/or TGF- β blockade at the single cell level on cells in the tumor and surrounding microenvironment. It also provides an example of how the data could be further leveraged translationally to identify novel approaches to overcome resistance to first generation immunotherapies, including anti-PD-L1 combination therapy.

For more details, please access the abstract online here.